391 filings
PRE 14A
BGNE
BeiGene Ltd
Preliminary proxy
15 Apr 24
4:27pm
8-K
BGNE
BeiGene Ltd
20 Mar 24
Departure of Directors or Certain Officers
4:10pm
8-K
BGNE
BeiGene Ltd
15 Mar 24
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
4:52pm
8-K
BGNE
BeiGene Ltd
8 Mar 24
Other Events
6:01am
10-K
2023 FY
BGNE
BeiGene Ltd
Annual report
26 Feb 24
6:16am
8-K
vfi1a wrg5k6tv
26 Feb 24
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
6:02am
8-K
yysqr lc098g7n
23 Jan 24
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
6:03am
8-K
zh8sq4f2eqnhde1
8 Dec 23
Other Events
6:01am
UPLOAD
rm56dxlp2a de3u
7 Dec 23
Letter from SEC
12:00am
8-K
m45r4s9r
9 Nov 23
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
4:08pm
8-K
u215b14cif1ec2itoh
20 Oct 23
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
4:04pm
CORRESP
scj49y ffj9
4 Oct 23
Correspondence with SEC
12:00am
8-K
xfuv1vim
21 Sep 23
Other Events
4:04pm
UPLOAD
qzy3x
21 Sep 23
Letter from SEC
12:00am
8-K
kh0r7393lt2102ccp
19 Sep 23
Termination of a Material Definitive Agreement
6:01am
8-K
yh4qdc
29 Aug 23
Results of Operations and Financial Condition
4:05pm
CORRESP
crz2s9
21 Aug 23
Correspondence with SEC
12:00am
8-K
i86zig9
2 Aug 23
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
6:13am